Invoking MCP tool get_variant_evidence with input {"diseaseName":"Neuroblastoma","therapyName":"Crizotinib","significance":"RESISTANCE"}
MCP tool get_variant_evidence returned meta=None content=[TextContent(type='text', text='{
  "Field Descriptions": "evidenceType: Category describing the type of clinical or biological evidence (e.g., predictive, diagnostic).\
evidenceDirection: Indicates whether the evidence supports or refutes the association.\
significance: The clinical relevance of the evidence.\
description: Detailed summary of the evidence from CIViC curators.\
evidenceLevel: Describes the robustness of the study type. A - Validated association, B - Clinical evidence, C - Case study, D - Preclinical evidence, and E - Inferential association\
evidenceRating: Quality score assigned to the evidence by curators (scored 1-5).\
url: Direct link to the CIViC record for this evidence item.\
When returning information to users you MUST cite URLs used for specific information.",
  "API Results": [
    {
      "status": "SUBMITTED",
      "evidenceType": "PREDICTIVE",
      "evidenceDirection": "SUPPORTS",
      "significance": "RESISTANCE",
      "molecularProfile": {
        "variants": [
          {
            "name": "F1174L",
            "feature": {
              "name": "ALK"
            }
          }
        ]
      },
      "disease": {
        "displayName": "Neuroblastoma"
      },
      "therapies": [
        {
          "name": "Crizotinib"
        }
      ],
      "variantOrigin": "SOMATIC",
      "description": "Activating mutations in the (ALK) gene are targeted by the dual-specific tyrosine kinase inhibitor crizotinib. The amino acid substitution F1174L resulted in a reduced response to crizotinib compared with other ALK-activating mutations. The amino acid substitution R1275Q resulted in an improved response to crizotinib.",
      "evidenceLevel": "B",
      "evidenceRating": null,
      "url": "https://identifiers.org/civic.eid:2345"
    },
    {
      "status": "ACCEPTED",
      "evidenceType": "PREDICTIVE",
      "evidenceDirection": "SUPPORTS",
      "significance": "RESISTANCE",
      "molecularProfile": {
        "variants": [
          {
            "name": "F1245C",
            "feature": {
              "name": "ALK"
            }
          }
        ]
      },
      "disease": {
        "displayName": "Neuroblastoma"
      },
      "therapies": [
        {
          "name": "Crizotinib"
        }
      ],
      "variantOrigin": "SOMATIC",
      "description": "A participant in Children\'s Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.  The patient showed progressive disease as best response after two 28-day cycles on crizotinib.",
      "evidenceLevel": "C",
      "evidenceRating": 3,
      "url": "https://identifiers.org/civic.eid:1333"
    },
    {
      "status": "ACCEPTED",
      "evidenceType": "PREDICTIVE",
      "evidenceDirection": "SUPPORTS",
      "significance": "RESISTANCE",
      "molecularProfile": {
        "variants": [
          {
            "name": "F1174L",
            "feature": {
              "name": "ALK"
            }
          }
        ]
      },
      "disease": {
        "displayName": "Neuroblastoma"
      },
      "therapies": [
        {
          "name": "Crizotinib"
        }
      ],
      "variantOrigin": "SOMATIC",
      "description": "Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.",
      "evidenceLevel": "D",
      "evidenceRating": 3,
      "url": "https://identifiers.org/civic.eid:125"
    }
  ]
}', annotations=None, meta=None)] structuredContent=None isError=False
### LLM OUTPUT ###
ALK
